Follow-Up of Patients Diagnosed With Germinal Testicular Tumors (Seminomas and Non-seminomatous) Treated With a Bone Marrow Transplant and a High Dose of Chemotherapy.
| Autor: | Zapata Laguado M; Clinical Oncology, Universidad El Bosque, Bogota, COL., Contreras Mejia F; Oncology, Instituto Nacional de Cancerología, Bogota, COL., Pereira Garzon M; Hematology, Instituto Nacional de Cancerología, Bogota, COL. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Jun 07; Vol. 16 (6), pp. e61887. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.61887 |
| Abstrakt: | Introduction: Germinal testicular tumors are the most common malignant neoplasm in men around 20 to 34 years. Even though they are unusual, they have increased incidence in the last decade; they have an excellent prognosis and overall survival at five years, approximately 95%. Divergent data exists regarding treatment options in patients with first, second, and third relapses with conventional therapy. Some studies describe the possible benefit of using high-dose chemotherapy associated with a bone marrow transplant with variable results. Methods: The present study describes clinical outcomes, clinical response, mortality, overall survival, and progression-free survival to two years in a group of patients with germinal malignant tumors, seminoma versus non-seminomatous with evidence of progression of the disease at first, second, or third conventional chemotherapy regimens, and who received high dose chemotherapy and bone marrow transplantation at the National Cancer Institute between 2010 and 2021. Results: A retrospective observational study of case series showed that 57% of patients in third-line therapy received high-dose chemotherapy and bone marrow transplantation, with progression disease median time from diagnosis more than two years. Patients in the post-graft period presented infectious complications (71%). The most common were febrile neutropenia (29%) with a mortality rate of 71% (n=5), progression-free survival of 2.3 months, and overall survival of 7.4 months. Conclusions: These results show that in this group of patients, regimens with high-dose chemotherapy associated with bone marrow transplants, have a worse prognosis compared to other cohorts of patients, and may not be the best candidates for this rescue therapy. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Ethics Committee for Research at Instituto Nacional de Cancerología issued approval R00082-21. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Zapata Laguado et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|